CompletedNot Applicable

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

United States20 participantsStarted 2025-09-23

Plain-language summary

This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participants must be 18 years or older.
✓. Participants must have a diagnosis of either obesity or overweight.
✓. Participants must have initiated first-time semaglutide treatment within the past 4-12 weeks for the management of overweight or obesity, in line with United States Prescribing Information (USPI) and the clinical judgment of the responsible Healthcare Professional (HCP).
✓. Participants must have access to and be able to use suitable weighing scales to record their weight before or during consultations.
✓. Participants must provide written informed consent to participate in this study, including agreeing to adhere to the associated procedures.

Exclusion criteria

✕. Participants with conditions that the Healthcare Professional (HCP) deems would prevent effective use of weighing scales and accurate self-monitoring or reporting of body weight.
✕. Failure to satisfy the responsible Healthcare Professional (HCP) of fitness to participate for any other reason.

What they're measuring

Percentage of participants who persisted on semaglutide treatment over the study period

Timeframe: 3 months

Trial details

NCT IDNCT07216651

SponsorClosed Loop Medicine

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-02-27

View on ClinicalTrials.gov More Obesity & Overweight trials